Malaria

The device is targeted at severely ill malaria patients who have been hospitalised and prescribed IV drug treatment. These are the most vulnerable patients, including children, pregnant women and immune deficient patients, and can have mortality rates up to 20%.

Latest News

Join our team: Product Development Biochemist/Microbiologist

Join our team: Product Development Biochemist/Microbiologist
Created on 12/13/2018 4:34:15 PM

We're looking for a Product Development Biochemist/Microbiologist to join our team. Find out more h...
Opportunities in the MediSieve R&D Team

Opportunities in the MediSieve R&D Team
Created on 12/13/2018 4:02:00 PM

We are looking to expand our laboratory team. We're looking for a mixture of skills, including in b...